Henrik Lövborg

891 total citations
26 papers, 720 citations indexed

About

Henrik Lövborg is a scholar working on Molecular Biology, Oncology and Toxicology. According to data from OpenAlex, Henrik Lövborg has authored 26 papers receiving a total of 720 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 8 papers in Oncology and 4 papers in Toxicology. Recurrent topics in Henrik Lövborg's work include Pharmacovigilance and Adverse Drug Reactions (4 papers), Cancer therapeutics and mechanisms (4 papers) and Ubiquitin and proteasome pathways (4 papers). Henrik Lövborg is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (4 papers), Cancer therapeutics and mechanisms (4 papers) and Ubiquitin and proteasome pathways (4 papers). Henrik Lövborg collaborates with scholars based in Sweden, Austria and Denmark. Henrik Lövborg's co-authors include Rolf Larsson, Joachim Gullbo, Peter Nygren, Linda Rickardson, Malin Wickström, Anders Isaksson, Robert Burman, Ulf Göransson, Sunithi Gunasekera and Erika Svangård and has published in prestigious journals such as British Journal of Cancer, International Journal of Cancer and Biochemical Pharmacology.

In The Last Decade

Henrik Lövborg

25 papers receiving 704 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Henrik Lövborg Sweden 15 435 178 92 73 70 26 720
Hans Weber Germany 11 589 1.4× 307 1.7× 72 0.8× 45 0.6× 77 1.1× 18 1.0k
Sue Chow Canada 19 700 1.6× 227 1.3× 189 2.1× 73 1.0× 66 0.9× 32 1.2k
Mohammad Sarwar Jamal Saudi Arabia 19 467 1.1× 203 1.1× 130 1.4× 67 0.9× 55 0.8× 37 992
Joan Cao United States 13 512 1.2× 260 1.5× 71 0.8× 88 1.2× 42 0.6× 21 1.3k
Qing Wen China 19 479 1.1× 162 0.9× 51 0.6× 89 1.2× 32 0.5× 41 926
Reinhard Kodym Austria 13 459 1.1× 169 0.9× 101 1.1× 51 0.7× 27 0.4× 29 802
Natalia F. Krynetskaia United States 18 630 1.4× 227 1.3× 71 0.8× 76 1.0× 71 1.0× 28 1.3k
Eva‐Laure Matera France 16 355 0.8× 314 1.8× 88 1.0× 40 0.5× 41 0.6× 32 815
Sarah Mackenzie United States 12 408 0.9× 116 0.7× 56 0.6× 54 0.7× 38 0.5× 20 628
Shun‐Ichiro Kageyama Japan 20 613 1.4× 273 1.5× 179 1.9× 82 1.1× 36 0.5× 52 1.1k

Countries citing papers authored by Henrik Lövborg

Since Specialization
Citations

This map shows the geographic impact of Henrik Lövborg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henrik Lövborg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henrik Lövborg more than expected).

Fields of papers citing papers by Henrik Lövborg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henrik Lövborg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henrik Lövborg. The network helps show where Henrik Lövborg may publish in the future.

Co-authorship network of co-authors of Henrik Lövborg

This figure shows the co-authorship network connecting the top 25 collaborators of Henrik Lövborg. A scholar is included among the top collaborators of Henrik Lövborg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henrik Lövborg. Henrik Lövborg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hakkarainen, Katja M., et al.. (2015). The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses’ reporting. European Journal of Clinical Pharmacology. 71(5). 631–636. 15 indexed citations
2.
Lövborg, Henrik, et al.. (2014). Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system. BMC Pharmacology and Toxicology. 15(1). 31–31. 9 indexed citations
3.
Lövborg, Henrik, et al.. (2012). A prospective analysis of the preventability of adverse drug reactions reported in Sweden. European Journal of Clinical Pharmacology. 68(8). 1183–1189. 13 indexed citations
4.
Lövborg, Henrik, Anna K. Jönsson, & Staffan Hägg. (2012). A Fatal Outcome After Unintentional Overdosing of Rivastigmine Patches. Current Drug Safety. 7(1). 30–32. 21 indexed citations
5.
Lövborg, Henrik, Robert Burman, & Joachim Gullbo. (2009). Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug. BMC Research Notes. 2(1). 114–114. 4 indexed citations
6.
Hassan, Saadia, Rolf Larsson, Stig Linder, et al.. (2009). Utilization of a right-handed coiled-coil protein from archaebacterium Staphylothermus marinus as a carrier for cisplatin.. PubMed. 29(1). 11–8. 25 indexed citations
7.
Rickardson, Linda, Malin Wickström, Rolf Larsson, & Henrik Lövborg. (2007). Image-Based Screening for the Identification of Novel Proteasome Inhibitors. SLAS DISCOVERY. 12(2). 203–210. 38 indexed citations
8.
Lövborg, Henrik, et al.. (2007). Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines.. PubMed. 26(6B). 4125–9. 29 indexed citations
9.
Rickardson, Linda, Mårten Fryknäs, Caroline Haglund, et al.. (2006). Screening of an annotated compound library for drug activity in a resistant myeloma cell line. Cancer Chemotherapy and Pharmacology. 58(6). 749–758. 31 indexed citations
10.
11.
Wickstrom, Mark, Henrik Lövborg, & Joachim Gullbo. (2006). Future Prospects for Old Chemotherapeutic Drugs in the Target-Specific Era; Pharmaceutics, Combinations, Co-Drugs and Prodrugs with Melphalan as an Example. Letters in Drug Design & Discovery. 3(10). 695–703. 4 indexed citations
12.
Wickström, Malin, Katarina Danielsson, Linda Rickardson, et al.. (2006). Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. Biochemical Pharmacology. 73(1). 25–33. 93 indexed citations
13.
Lövborg, Henrik, Fredrik Öberg, Linda Rickardson, et al.. (2005). Inhibition of proteasome activity, nuclear factor-KB translocation and cell survival by the antialcoholism drug disulfiram. International Journal of Cancer. 118(6). 1577–1580. 102 indexed citations
14.
Rickardson, Linda, Mårten Fryknäs, Sumeer Dhar, et al.. (2005). Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. British Journal of Cancer. 93(4). 483–492. 67 indexed citations
15.
Gullbo, Joachim, Henrik Lövborg, Sumeer Dhar, et al.. (2004). Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828. Anti-Cancer Drugs. 15(1). 45–54. 4 indexed citations
16.
Lövborg, Henrik, Peter Nygren, & Rolf Larsson. (2004). Multiparametric evaluation of apoptosis: Effects of standard cytotoxic agents and the cyanoguanidine CHS 828. Molecular Cancer Therapeutics. 3(5). 521–526. 43 indexed citations
17.
Wojciechowski, Jacek, Henrik Lövborg, & Józefa Węsierska‐Gądek. (2003). Activation of p53 protein in normal and in tumor cells by a novel anticancer agent CHS 828.. PubMed. 29(2). 53–67. 3 indexed citations
18.
Gullbo, Joachim, Charlotta Wallinder, Henrik Lövborg, et al.. (2003). Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2.. PubMed. 2(12). 1331–9. 7 indexed citations
19.
Lövborg, Henrik, et al.. (2002). Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells. Biochemical Pharmacology. 63(8). 1491–1498. 11 indexed citations
20.
Lövborg, Henrik, et al.. (2001). Modulation of cell death and metabolic effects by 3-aminobenzamide in U-937 GTB cells exposed to CHS 828. Biochemical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hans Weber Breakdown of academic impact, for papers by Sue Chow Breakdown of academic impact, for papers by Mohammad Sarwar Jamal Breakdown of academic impact, for papers by Joan Cao Breakdown of academic impact, for papers by Qing Wen Breakdown of academic impact, for papers by Reinhard Kodym Breakdown of academic impact, for papers by Natalia F. Krynetskaia Breakdown of academic impact, for papers by Eva‐Laure Matera Breakdown of academic impact, for papers by Sarah Mackenzie Breakdown of academic impact, for papers by Shun‐Ichiro Kageyama
Rankless by CCL
2026